Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile

Product Code DAT19539
Publication Date June 2010
Publisher Datamonitor
Product Type Report
Pages 64
ISBN Number not applicable
Change currency
PDF £3,605.00 €4,341 $5,700 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the Rx drug sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Key reasons to purchase this research

  • Benchmark Mitsubishi Tanabe's performance against key rivals in the prescription pharmaceutical sector
  • Assess how the merger of Mitsubishi and Tanabe has provided scale, re-focused the company's strategic priorities and resource capabilities
  • Assess how Mitsubishi Tanabe's launch portfolio is forecast to offset the sluggish sales growth of its aging marketed portfolio

Contents

  • Executive Summary
    • Key findings
    • Prescription pharmaceutical sales and growth rate performance, 2002–14
    • Financial performance, 2002–14
    • Mitsubishi Tanabe: PharmaVitae forecasts at a glance
    • Strategic insight
      • 2002–06: Tanabe’s historical sales driven by Remicade uptake
      • 2007: Tanabe and Mitsubishi merger – amid a wave of Japanese consolidation
      • 2008–14: Greater scale, but slow growth
  • SWOT Analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Quarterly Update
    • Latest prescription pharma product news
      • Q4 2009
      • Q3 2009
      • Q2 2009
      • Q1 2009
      • Q4 2008
    • Latest corporate news
      • Q3 2009
      • Q2 2009
      • Q1 2009
      • Q4 2008
    • Future product milestones
  • Company Introduction
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
      • Merger of Mitsubishi Pharma and Tanabe Seiyaku
      • M&A history - Mitsubishi Pharma
      • M&A history - Tanabe Seiyaku
      • M&A strategy
    • Current corporate structure
    • Pharmaceuticals segment
    • Other business segment
  • Company Sales
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2002–14
    • Product analysis
      • Product analysis, 2002–08
      • Product analysis, 2008–14
    • Therapy area analysis
    • Geographic analysis
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2008–14
    • Core analysis, 2008–14
    • Expiry analysis, 2008–14
    • Launch/core/expiry configuration, 2008–14
    • Molecule type analysis
    • Externalization analysis
  • Company Financials
    • Key findings
    • Reconciliation between
    • PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002–08
    • Operating costs and profit analysis
      • Operating costs and profit analysis, 2002–08
      • Operating cost ratio and profit margin analysis, 2002–08
      • Operating cost ratio and profit margin analysis, 2008–14
      • Operating costs and profit analysis, 2008–14
  • Appendix
    • Abbreviations
    • Exchange rates
  • Tables
    • Table: Mitsubishi Tanabe – PharmaVitae forecasts at a glance
    • Table: Mitsubishi Tanabe upcoming milestones
    • Table: Mitsubishi Tanabe product portfolio overview ($m), 2002–08
    • Table: Mitsubishi Tanabe product portfolio overview ($m), 2008–14
    • Table: Mitsubishi Tanabe prescription pharmaceutical sales by therapy area ($m), 2008–14
    • Table: Mitsubishi Tanabe prescription pharmaceutical sales by geographic region ($m), 2008–14
    • Table: Mitsubishi Tanabe launch portfolio overview ($m), 2008–14
    • Table: Mitsubishi Tanabe core portfolio overview ($m), 2008–14
    • Table: Mitsubishi Tanabe expiry portfolio overview ($m), 2008–14
    • Table: Mitsubishi Tanabe prescription pharmaceutical sales by molecule type ($m), 2008–14
    • Table: Mitsubishi Tanabe prescription pharmaceutical sales by source ($m), 2008–14
    • Table: Total Mitsubishi Tanabe sales by business unit ($m), 2002–08
    • Table: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2002–08
    • Table: Mitsubishi Tanabe operating cost ratio analysis (% of total revenues), 2002–08
    • Table: Mitsubishi Tanabe operating cost ratio analysis (% of total revenues), 2008–14
    • Table: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2008–14
    • Table: Exchange rates, 2009
  • Figures
    • Figure: The PharmaVitae Explorer
    • Figure: Mitsubishi Tanabe prescription pharmaceutical sales ($m) and growth rate (%) 2002–14
    • Figure: Mitsubishi Tanabe’s financial performance ($m), 2002–14
    • Figure: Tanabe Seiyaku’s historical prescription pharmaceutical performance, 2002–06 ($m)
    • Figure: Japan Pharma peer set, company ranking by prescription pharmaceutical sales, 2002–14 ($m)
    • Figure: Mitsubishi Tanabe prescription pharmaceutical sales by source, 2002–14, ($m)
    • Figure: Mitsubishi Tanabe SWOT analysis
    • Figure: M&A/divestment history
    • Figure: Current corporate structure
    • Figure: Mitsubishi Tanabe prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002–14
    • Figure: Key product sales ($m), 2002–14
    • Figure: Mitsubishi Tanabe key sales growth drivers and resistors ($m), 2002–08
    • Figure: Mitsubishi Tanabe key sales growth drivers and resistors ($m), 2008–14
    • Figure: Mitsubishi Tanabe prescription pharmaceutical sales by therapy area ($m), 2002–14
    • Figure: Mitsubishi Tanabe prescription pharmaceutical sales by geographic region ($m), 2002–14
    • Figure: Mitsubishi Tanabe launch/core/expiry configuration ($m), 2008–14
    • Figure: Mitsubishi Tanabe prescription pharmaceutical sales by molecule type ($m), 2002–14
    • Figure: Mitsubishi Tanabe prescription pharmaceutical sales by source ($m), 2002–14
    • Figure: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2002–14